Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02067104 · ClinicalTrials.gov registry record · Phase 2
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
A Phase 2 study, sponsored by University of Arizona.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02067104 is a Phase 2 study that was terminated before completion, run by University of Arizona. The registered enrollment target is 9 participants.
The verdict
NCT02067104, a Phase 2 study, was terminated before completion, sponsored by University of Arizona.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is a single site double blinded Phase II study to evaluate the chemopreventative effectiveness of vismodegib in the treatment of subjects at high risk for developing basal cell carcinomas (BCC).
Interventions
- DRUG Placebo
- DRUG Vismodegib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2014-02-17 |
| Est. Completion | 2016-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02067104
The ClinicalTrials.gov registry entry for NCT02067104 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02067104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02067104 about?
NCT02067104 is a clinical study titled "Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention". This study is a single site double blinded Phase II study to evaluate the chemopreventative effectiveness of vismodegib in the treatment of subjects at high risk for developing basal cell carcinomas (BCC).
What is the current status of trial NCT02067104?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2014-02-17. Estimated completion is 2016-12-31.
What interventions are being tested in trial NCT02067104?
The interventions under investigation include: Placebo (DRUG), Vismodegib (DRUG).
Who is sponsoring clinical trial NCT02067104?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.